An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard, Gedske Daugaard, Jean-Pascal Machiels, William Conkright, Sunil Sharma, Patricia M. M. B. Soetekouw, Jeffrey Yachnin, Lisa Sengelov, Peter Van Veldhuizen, Sanjiv S. Agarwala, Dorothee Semiond, Mustapha Chadjaa, Liji Shen, James L. Wade

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1241-1252
JournalCancer Chemotherapy and Pharmacology
Volume73
Issue number6
DOIs
Publication statusPublished - Jun 2014

Keywords

  • Cabazitaxel
  • QTc interval
  • Cardiac safety
  • Advanced solid tumors
  • Pharmacokinetics
  • ECG

Cite this

Maison-Blanche, P., Dakhil, S., Baron, A., Rottey, S., Millard, F., Daugaard, G., Machiels, J-P., Conkright, W., Sharma, S., Soetekouw, P. M. M. B., Yachnin, J., Sengelov, L., Van Veldhuizen, P., Agarwala, S. S., Semiond, D., Chadjaa, M., Shen, L., & Wade, J. L. (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 73(6), 1241-1252. https://doi.org/10.1007/s00280-014-2460-6